158 related articles for article (PubMed ID: 10580404)
1. Resistance of the human immunodeficiency virus to the inhibitory action of negatively charged albumins on virus binding to CD4.
Cabrera C; Witvrouw M; Gutiérrez A; Clotet B; Kuipers ME; Swart PJ; Meijer DK; Desmyter J; De Clercq E; Esté JA
AIDS Res Hum Retroviruses; 1999 Nov; 15(17):1535-43. PubMed ID: 10580404
[TBL] [Abstract][Full Text] [Related]
2. Novel, negatively charged, human serum albumins display potent and selective in vitro anti-human immunodeficiency virus type 1 activity.
Jansen RW; Schols D; Pauwels R; De Clercq E; Meijer DK
Mol Pharmacol; 1993 Nov; 44(5):1003-7. PubMed ID: 7902528
[TBL] [Abstract][Full Text] [Related]
3. Anti-HIV-1 activity of combinations and covalent conjugates of negatively charged human serum albumins (NCAs) and AZT.
Kuipers ME; Swart PJ; Witvrouw M; Esté JA; Reymen D; De Clercq E; Meijer DK
J Drug Target; 1999; 6(5):323-35. PubMed ID: 10342381
[TBL] [Abstract][Full Text] [Related]
4. The influence of charge clustering on the anti-HIV-1 activity and in vivo distribution of negatively charged albumins.
Beljaars L; Floris R; Berkhout B; Smit C; Meijer DK; Molema G
Biochem Pharmacol; 2002 May; 63(9):1663-73. PubMed ID: 12007569
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of anti-HIV activity of succinylated human serum albumin.
Kuipers ME; vd Berg M; Swart PJ; Laman JD; Meijer DK; Koppelman MH; Huisman H
Biochem Pharmacol; 1999 Apr; 57(8):889-98. PubMed ID: 10086322
[TBL] [Abstract][Full Text] [Related]
6. Potent inhibition of replication of primary HIV type 1 isolates in peripheral blood lymphocytes by negatively charged human serum albumins.
Groenink M; Swart PJ; Broersen S; Kuipers M; Meijer DK; Schuitemaker H
AIDS Res Hum Retroviruses; 1997 Jan; 13(2):179-85. PubMed ID: 9007203
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and anti-HIV-1 efficacy of negatively charged human serum albumins in mice.
Kuipers ME; Swart PJ; Schutten M; Smit C; Proost JH; Osterhaus AD; Meijer DK
Antiviral Res; 1997 Jan; 33(2):99-108. PubMed ID: 9021051
[TBL] [Abstract][Full Text] [Related]
8. T-cell-line-tropic human immunodeficiency virus type 1 that is made resistant to stromal cell-derived factor 1alpha contains mutations in the envelope gp120 but does not show a switch in coreceptor use.
Schols D; Esté JA; Cabrera C; De Clercq E
J Virol; 1998 May; 72(5):4032-7. PubMed ID: 9557691
[TBL] [Abstract][Full Text] [Related]
9. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).
Marozsan AJ; Kuhmann SE; Morgan T; Herrera C; Rivera-Troche E; Xu S; Baroudy BM; Strizki J; Moore JP
Virology; 2005 Jul; 338(1):182-99. PubMed ID: 15935415
[TBL] [Abstract][Full Text] [Related]
10. Polyanionic (i.e., polysulfonate) dendrimers can inhibit the replication of human immunodeficiency virus by interfering with both virus adsorption and later steps (reverse transcriptase/integrase) in the virus replicative cycle.
Witvrouw M; Fikkert V; Pluymers W; Matthews B; Mardel K; Schols D; Raff J; Debyser Z; De Clercq E; Holan G; Pannecouque C
Mol Pharmacol; 2000 Nov; 58(5):1100-8. PubMed ID: 11040059
[TBL] [Abstract][Full Text] [Related]
11. Comparative pharmacokinetic, immunologic and hematologic studies on the anti-HIV-1/2 compounds aconitylated and succinylated HSA.
Swart PJ; Beljaars E; Smit C; Pasma A; Schuitemaker H; Meijer DK
J Drug Target; 1996; 4(2):109-16. PubMed ID: 8894971
[TBL] [Abstract][Full Text] [Related]
12. Human immunodeficiency virus glycoprotein gp120 as the primary target for the antiviral action of AR177 (Zintevir).
Esté JA; Cabrera C; Schols D; Cherepanov P; Gutierrez A; Witvrouw M; Pannecouque C; Debyser Z; Rando RF; Clotet B; Desmyter J; De Clercq E
Mol Pharmacol; 1998 Feb; 53(2):340-5. PubMed ID: 9463493
[TBL] [Abstract][Full Text] [Related]
13. The in vitro anti-HIV efficacy of negatively charged human serum albumin is antagonized by heparin.
Swart PJ; Sun CS; Kuipers ME; Asuncion C; Josephs S; Smit C; Meijer DK
AIDS Res Hum Retroviruses; 1997 May; 13(8):677-83. PubMed ID: 9168236
[TBL] [Abstract][Full Text] [Related]
14. Biological and genetic characterization of a human immunodeficiency virus strain resistant to CXCR4 antagonist T134.
Kanbara K; Sato S; Tanuma J; Tamamura H; Gotoh K; Yoshimori M; Kanamoto T; Kitano M; Fujii N; Nakashima H
AIDS Res Hum Retroviruses; 2001 May; 17(7):615-22. PubMed ID: 11375057
[TBL] [Abstract][Full Text] [Related]
15. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.
Westby M; Smith-Burchnell C; Mori J; Lewis M; Mosley M; Stockdale M; Dorr P; Ciaramella G; Perros M
J Virol; 2007 Mar; 81(5):2359-71. PubMed ID: 17182681
[TBL] [Abstract][Full Text] [Related]
16. The anti-HIV activity of ADS-J1 targets the HIV-1 gp120.
Armand-Ugón M; Clotet-Codina I; Tintori C; Manetti F; Clotet B; Botta M; Esté JA
Virology; 2005 Dec; 343(1):141-9. PubMed ID: 16168454
[TBL] [Abstract][Full Text] [Related]
17. Anti-human immunodeficiency virus activity of novel aminoglycoside-arginine conjugates at early stages of infection.
Cabrera C; Gutiérrez A; Blanco J; Barretina J; Litovchick A; Lapidot A; Evdokimov AG; Clotet B; Esté JA
AIDS Res Hum Retroviruses; 2000 May; 16(7):627-34. PubMed ID: 10791873
[TBL] [Abstract][Full Text] [Related]
18. Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4.
Zhao Q; Ma L; Jiang S; Lu H; Liu S; He Y; Strick N; Neamati N; Debnath AK
Virology; 2005 Sep; 339(2):213-25. PubMed ID: 15996703
[TBL] [Abstract][Full Text] [Related]
19. Discovery of small-molecule human immunodeficiency virus type 1 entry inhibitors that target the gp120-binding domain of CD4.
Yang QE; Stephen AG; Adelsberger JW; Roberts PE; Zhu W; Currens MJ; Feng Y; Crise BJ; Gorelick RJ; Rein AR; Fisher RJ; Shoemaker RH; Sei S
J Virol; 2005 May; 79(10):6122-33. PubMed ID: 15857997
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of anti-HIV activity of negatively charged albumins: biomolecular interaction with the HIV-1 envelope protein gp120.
Kuipers ME; Huisman JG; Swart PJ; de Béthune MP; Pauwels R; Schuitemaker H; De Clercq E; Meijer DK
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Apr; 11(5):419-29. PubMed ID: 8605586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
